Cascade Chemistry Eyes Bulk Amphetamines, Oxycodone Production Approval
Published Date: 1/31/2025
Notice
Summary
Organic Consultants LLC, also known as Cascade Chemistry, wants to become a big-time maker of important controlled drugs like amphetamines and oxycodone. If you’re already registered or interested, you can share your thoughts or ask for a hearing by April 1, 2025. This move could impact drug manufacturing and supply, so keep an eye on the deadline and get involved if you want to!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
New Supplier of Schedule II Standards
On November 26, 2024, Organic Consultants LLC (Cascade Chemistry) applied to be registered as a bulk manufacturer of Schedule II controlled substances including amphetamine, methylphenidate, oxycodone, fentanyl, methadone, and morphine. The company says it plans to bulk manufacture small quantities to use internally or to sell as analytical reference standard materials to its customers.
Registration Limited to Standards Only
The notice states that, if registered, no other activities for the listed drug codes are authorized beyond bulk manufacture of small quantities for internal use or sale as analytical reference standard materials. The application and any comments or hearing requests must be submitted by April 1, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-02001, Melamine From Germany, Qatar, and Trinidad and Tobago: Countervailing Duty Orders
The U.S. is putting extra taxes on melamine imports from Germany, Qatar, and Trinidad and Tobago because these countries got unfair help from their governments. This move protects American melamine makers from harm starting January 31, 2025. If you import or sell melamine, get ready for these new costs and rules!
Next: 2025-02013, Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of a controlled substance called MDMA, which is a Schedule I drug. People who make or use these drugs can share their thoughts or ask for a hearing by March 3, 2025. This move could impact companies involved in drug manufacturing and regulation, with no direct cost changes mentioned yet.